Automating Pulmonology Specialty Drug Prior Auth for Respiratory Therapies

Klivira delivers precise automation for pulmonology specialty drug prior auth, ensuring timely approvals for high-cost respiratory therapies and biologics. Our platform streamlines complex workflows from prescription to fulfillment.

Revenue cycle directors and prior authorization coordinators in pulmonology face significant challenges managing the PA process for specialty drugs. The intricate requirements for biologics, antifibrotics, and advanced respiratory therapies, coupled with the medical versus pharmacy benefit divide, demand a robust and accurate automation solution to mitigate delays and denials.

The Complex Landscape of Pulmonology Specialty Drug Prior Authorization

Prior authorization for specialty drugs in pulmonology involves navigating a high-stakes environment where therapies like asthma biologics, IPF antifibrotics, and even home oxygen often require extensive documentation. The distinction between medical and pharmacy benefit pathways adds layers of complexity, frequently leading to misrouted submissions and delayed patient access to critical treatments. This necessitates an automated approach that accurately identifies the correct benefit and submission channel.

Common Prior Authorization Triggers in Pulmonology

Asthma biologics, including omalizumab (Xolair), mepolizumab (Nucala), dupilumab (Dupixent), and tezepelumab (Tezspire), often requiring eosinophil count and step-therapy documentation.
IPF antifibrotics such as pirfenidone (Esbriet) and nintedanib (Ofev), which demand specific clinical criteria.
COPD specialty drugs and advanced triple-therapy inhalers, where step-therapy protocols are frequently enforced by payers.
Home oxygen and BiPAP/CPAP equipment, which involve distinct medical necessity guidelines.
Lung transplant evaluation and associated immunosuppression therapies.

Navigating Clinical Guidelines and Documentation Requirements

Pulmonology prior authorizations are heavily informed by established clinical guidelines such as ATS guidelines, GOLD for COPD, and GINA for asthma. For biologics, specific documentation like peripheral eosinophil counts, history of prior controller therapy at maximum dose, and exacerbation history are critical. Common denial reasons include failure to meet step-therapy requirements or insufficient eosinophil-count thresholds for IL-5-targeting biologics, highlighting the need for precise data capture and submission.

Klivira's Automated Workflow for Pulmonology Specialty Drugs

**Automated Benefit-Side Determination:** Klivira's policy engine accurately identifies whether a pulmonology specialty drug falls under the medical or pharmacy benefit, per drug, per payer, and per patient context.
**Multi-Channel Routing:** Pharmacy-benefit drugs route via ePA partners like CoverMyMeds and Surescripts using NCPDP SCRIPT ePA, while medical-benefit drugs utilize provider portals, X12 278, or Da Vinci PAS where available.
**Step-Therapy and Documentation Automation:** Our platform leverages FHIR MedicationRequest and Observation resources to capture and populate essential step-therapy and prior-line therapy documentation from the EMR.
**Site-of-Care Logic:** Klivira surfaces payer site-of-care policies for medical-benefit specialty drugs, ensuring submissions align with requirements to avoid denials.
**Specialty Pharmacy Fulfillment Handoff:** We coordinate the post-approval specialty-pharmacy fulfillment workflow, reducing delays in patient access to medication.

Seamless EMR Integration and Payer Connectivity

Klivira integrates directly with your EMR system, leveraging standards like SMART on FHIR to extract the necessary clinical data for pulmonology prior authorizations. This deep integration ensures that critical information, from diagnosis codes to eosinophil counts, is accurately and efficiently transmitted. Our robust connectivity to a wide array of payer portals and ePA channels, including X12 278 and Da Vinci PAS, ensures comprehensive coverage across the payer landscape, facilitating rapid and compliant submissions.

Frequently asked questions

How does Klivira handle the medical vs. pharmacy benefit split for pulmonology specialty drugs?

Klivira's policy engine automatically determines the correct benefit side (medical or pharmacy) for each pulmonology specialty drug based on the specific drug, payer, and patient context. This eliminates common misclassification errors and ensures the PA request is routed to the appropriate channel, whether it's through a PBM's ePA process or the payer's medical PA channel.

What clinical guidelines does Klivira incorporate for asthma biologic prior authorizations?

Klivira's automation logic is designed to be aware of established clinical guidelines such as GINA for asthma, GOLD for COPD, and ATS guidelines. For asthma biologics, this includes automating the documentation of eosinophil counts, prior controller therapy at maximum dose, and exacerbation history, aligning with payer requirements derived from these guidelines.

How does Klivira address common denial reasons like step-therapy for pulmonology drugs?

Klivira directly addresses step-therapy denials by automating the capture and submission of prior-line therapy documentation. By reading medication history from FHIR MedicationRequest resources, our platform ensures that payer-required trials of high-dose ICS-LABA or other conservative therapies are adequately documented, preventing common step-therapy related denials.

Can Klivira integrate with our existing EMR for pulmonology PA workflows?

Yes, Klivira is designed for seamless integration with existing EMR systems. We leverage standards like SMART on FHIR to extract relevant clinical data, such as diagnosis codes, medication history, and lab results (e.g., eosinophil counts), directly from your EMR. This ensures that all necessary documentation for pulmonology specialty drug prior authorizations is readily available for submission.

Does Klivira help with specialty pharmacy fulfillment coordination?

Yes, for pharmacy-benefit specialty drugs, Klivira coordinates the post-approval specialty pharmacy fulfillment workflow. While Klivira doesn't manage program enrollment itself, it facilitates the handoff to the payer's specialty pharmacy partner (e.g., Accredo, CVS Specialty, Optum Specialty) after PA approval, helping to reduce overall time-to-medication for patients.